

Antibiotice confirms upward trend by the 2005 results

The financial results reported by the pharmaceutical producer, Antibiotice, for 2005 confirm the constant upward trend of the company in last years. In 2005, Antibiotice reported a turnover of 45.2 million EUR (i.e. 163.5 million RON), 35% higher than that of 2004. The gross profit of the company also increased by 51% reaching 6.5 million EUR (i.e. 23.7 million RON) at the end of 2005.

The significant increase in Antibiotice's turnover is primarily the result of the consolidation of the position held by the company on the market in the segments of antiinfectives, dermatologicals and topical preparations (therapeutic classes for which the producer holds market shares between 60 and 80% in terms of volume), as well as of the development of new products intended for cardiovascular and central nervous system therapy – products which account for approximately 10% of the company's turnover. The reorganization of the marketing and promotion structures by enlarging the national team of medical representatives was also a decisive drive in the increase of the volume of sales and implicitly, of the turnover.